This book includes a plain text version that is designed for high accessibility. To use this version please follow this link.
11-09 :: September 2011


nanotimes Patents


ding to the patent, NanoCap has potentially higher energy storage densities compared to existing lithium ion batteries. The device has low weight, enhanced capacitance and higher power. Once completely de- veloped, NanoCap can be used to power an exten- sive range of applications such as consumer batteries used in computers and cell phones, transistor gate dielectrics, transportation, telecommunication infra- structure and energy storage system, specifically for storing renewable energy.


http://www.daisanalytic.com


h t t p : / / p a t f t . u s p t o . g o v / n e t a c g i / n p h - Parser?patentnumber=7990679


57


pharmacological effects and a considerably improved quality of patients’ life.


The product is of particular interest for pharmaceuti- cal manufacturers and developers of active agents for the treatment of pulmonary hypertension.


Contact: TransMIT GmbH, Ms. Iris Stallkamp, Kerkrader Str. 3, D-35394 Giessen, Germany, Phone: +49-(0)641- 94364-33


h t t p : / /www. h i p o - o n l i n e . d e / u k / u k _ d own -


load.cfm?expose_Id=566&pdf_name=TM543_ Expose_200611b_englisch_2011-08-10.pdf


Nanoparticles for Sustained Release of Active Agents for the Treatment of Pulmonary Hypertension


Inventor(s): Tobias Gessler, Thomas Kissel, Thomas Schmehl, Moritz Beck-Broichsitter


Abstract: Pulmonary hypertension is a serious, lifethreatening disorder which substantially restricts physical capaci- ties and results in a severely reduced life expectancy with an average survival time of only 2.8 years after diagnosis if the disease is not treated. The new nano- particles now allow a controlled release of inhalable active agents for pulmonary hypertension over a long period of time, thus leading to a prolongation of


Substances for the Effective Stimulation of Natriuretic Peptide Receptors


Inventor(s): Thomas Walther, Anja Schwiebs


Abstract: The natriuretic system in humans and animals com- prises receptors for the atrial natriuretic peptide (ANP), the B-type natriuretic peptide (BNP), and the C-type natriuretic peptide (CNP), and plays an essen- tial role in regulating blood pressure and the body‘s fluid balance. The natriuretic peptides which bind to the relevant receptors cause blood pressure to decre- ase and water excretion via urine to increase. Fur- thermore, they comprise direct cardioprotective and antifibrotic effects.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67